Volume 1, Issue 1 (2015)                   Pharm Biomed Res 2015, 1(1): 26-31 | Back to browse issues page


XML Print


1- Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2- Research Student Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:   (6224 Views)

Bleomycin (BLM) as an anti-cancer agent causes tissue toxicities through DNA damaging and cell deaths. The aim of this study was to investigate the effects of thymol against genotoxicity and anti-proliferation induced by BLM in normal human lymphocytes and ovarian cancer cells. Peripheral blood samples were collected from human volunteers and were incubated with thymol at different concentrations at 50, 100, and 150 μM. After 2 h incubation, the whole blood was treated with BLM. Then the lymphocytes were cultured with mitogenic stimulation to determine the micronuclei in cytokinesis blocked binucleated lymphocyte. Human ovarian cancer cells (SKOV-3) were treated with thymol at various concentrations and/or BLM with their combinations and then cell viability were evaluated. Incubation of whole blood with thymol exhibited a significant decrease in the incidence of micronuclei in lymphocytes caused by BLM, as compared with similarly BLM-treated lymphocytes without thymol. Neither enhanced cell death nor cell protective effect was observed using thymol pre-treatment of SKOV-3 cells. This study showed that thymol selectively protects human lymphocytes against DNA damage induced by BLM without any protection on cancer cell. This result is promising for using this natural product in treatment of ovarian cancer with BLM.

Full-Text [PDF 334 kb]   (2933 Downloads)    
Type of Study: Original Research | Subject: Oncology

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.